ENANTA PHARMACEUTICALS, INC Excess Tax Benefit from Share-based Compensation, Financing Activities
ENANTA PHARMACEUTICALS, INC (ENTA) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $213.00 thousand for the 12-month period ending 2017-09-30, per its 10-K filed 2019-11-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-11-27
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was -$2.00K.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $1.70M.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-09-30 was -$3.00K, a 160.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-06-30 was -$102.00K.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $213.00K, a 87.81% decline from fiscal 2016.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $1.75M, a 3.69% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $1.81M, a 1549.09% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $110.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2017-09-30 | $213.00K 10-K · filed 2019-11-27 | |||
| 2016-09-30 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $1.70M derived: sum of 2 quarters · filed 2018-11-29 | $1.75M 10-K · filed 2018-11-29 | |
| 2016-06-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | $1.75M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $48.00K 10-Q · filed 2017-05-10 | |||
| 2015-09-30 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | -$105.00K derived: sum of 2 quarters · filed 2017-12-11 | -$105.00K derived: sum of 3 quarters · filed 2017-12-11 | $1.81M 10-K · filed 2017-12-11 |
| 2015-06-30 | -$102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | -$102.00K derived: sum of 2 quarters · filed 2016-08-09 | $1.82M 10-Q · filed 2016-08-09 | $1.82M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $1.92M 10-Q · filed 2016-05-10 | $1.92M derived: sum of 3 quarters · filed 2016-12-09 | |
| 2014-12-31 | $1.92M 10-Q · filed 2016-02-09 | $1.92M derived: sum of 2 quarters · filed 2016-12-09 | ||
| 2014-09-30 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $110.00K 10-K · filed 2016-12-09 | ||
| 2014-06-30 | $105.00K 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |